Freemont Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Freemont Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.9M	Sell	6,500 -700	-10%	-$326K	0.44%	73
2025 Q4	$3.26M	Buy	7,200 +4,800	+200%	+$2.07M	0.57%	49
2025 Q3	$940K	Sell	2,400 -17,600	-88%	-$7.36M	0.47%	51
2025 Q2	$8.9M	Buy	20,000 +14,200	+245%	+$6.54M	1.33%	25
2025 Q1	$2.81M	Sell	5,800 -600	-9%	-$280K	0.92%	40
2024 Q4	$2.58M	Hold	6,400	–	–	1.12%	29
2024 Q3	$2.98M	Hold	6,400	–	–	1.46%	20
2024 Q2	$3M	Sell	6,400 -31,300	-83%	-$13.6M	1.42%	14
2024 Q1	$15.8M	Sell	37,700 -11,700	-24%	-$4.95M	2.25%	10
2023 Q4	$20.1M	Hold	49,400	–	–	2.53%	11
2023 Q3	$17.2M	Sell	49,400 -8,300	-14%	-$2.9M	2.57%	10
2023 Q2	$20.3M	Hold	57,700	–	–	2.45%	9
2023 Q1	$18.2M	Hold	57,700	–	–	2.55%	9
2022 Q4	$16.7M	Buy	57,700 +17,200	+42%	+$5.24M	2.61%	9
2022 Q3	$11.7M	Buy	40,500 +19,700	+95%	+$5.67M	2.14%	11
2022 Q2	$5.86M	Sell	20,800 -1,200	-5%	-$321K	1.01%	40
2022 Q1	$5.74M	Buy	+22,000	New	+$5.22M	0.87%	52
2021 Q3	–	Sell	-32,000	Closed	-$6.25M	–	116
2021 Q2	$6.45M	Hold	32,000	–	–	0.93%	46
2021 Q1	$6.88M	Hold	32,000	–	–	1.12%	43
2020 Q4	$7.56M	Buy	+32,000	New	+$7.34M	1.41%	36

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Freemont Management's VRTX Position: Q1 2026 in Review

Freemont Management reduced its Vertex Pharmaceuticals (VRTX) stake by 9.7% in Q1 2026, selling an estimated $326K and leaving 6,500 shares worth $2.9M. The position accounts for 0.44% of the portfolio, ranked #73.

Freemont Management first reported a position in VRTX in Q4 2020 and has held it in 20 quarters since. The position peaked at $20.3M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Freemont Management held 6,500 shares of Vertex Pharmaceuticals worth $2.9M as of Q1 2026.
Freemont Management sold 700 Vertex Pharmaceuticals shares in Q1 2026, an estimated $326K.
Vertex Pharmaceuticals made up 0.44% of Freemont Management's portfolio in Q1 2026, its #73 holding.
Freemont Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 20 quarters since.
Freemont Management's Vertex Pharmaceuticals position peaked at $20.3M in Q2 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Freemont Management's 13F filing for Q1 2026, filed 6 May 2026.